Cara Mosley,Dennis C. Liotta,James P. Snyder,Lawrence Wilson,RAYMONJD J. DINGLEDINE,Scott Myers,Stephen F. Traynelis,YESIM ALTAS TAHIROVIC
申请号：
BRPI0813001
公开号：
BRPI0813001A2
申请日:
2008.06.30
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: wherein: each (L)k-Ar1 is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl； W is a bond, alkyl, or alkenyl； X is a bond, NR1 or O and each R1 and R2 is independently H, alkyl, alkenyl or aralkyl or R1 and R2 taken together form a 5-8 membered ring； R3&minus；R6 are selected from certain specific substituents or a carbonyl； Y is a bond, O, S, SO, SO2, CH2, NH, N(alkyl), or NHC(&boxH；O)； and Z is OH, NR6R7, NR8SO2(alkyl), NR8C(O)NR6R7, NR8C(O)O(alkyl), NR8-dihydrothiazole, or NR8-dihydroimidazole or wherein Z can fuse with Ar2 to form selected heterocycles.
